Volume 7, Number 2
Dear Colleagues and Readers,
This issue of CTT Journal is produced before the XII International R. Gorbacheva Memorial Symposium Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy (St. Petersburg, 20-22 September, 2018). Thus this issue of CTT Journal contains several articles which reflect the important areas of clinical research in the field of hematopoietic stem cell transplantation which were not covered by the main scientific program of the Symposium. Therefore, I would like to express my deep gratitude to the authors who have positively responded to our invitation and contributed with their studies to this issue of CTT which will be published just before the Symposium.
I would like to highlight the novel educational trend in the journal, which addresses the current controversies in the field of stem cell transplantation. A concise, but conceptual article Transplants for acute myeloid leukemia in 1st remission: statisticians, magicians and the rest of us was published by Prof. Robert P. Gale in CTT No.4 (2017) has drawn a significant attention of Journal’s audience. The author’s opinion about role and ability of modern statistics to assess risk factors when deciding allogeneic hematopoietic stem cell transplantation (allo-HCT) has initiated an interesting discussion concerning the role, optimal timing and risk factors of allo-HCT in first remission of acute myeloblastic leukemia.
I hope that this article by R. Gale, a reply by Dr. Ivan S. Moiseev (CTT v.7, No.1), and concluding remarks by Prof. Axel R. Zander published in the this CTT issue have drawn attention to the complex problem of clinical risk evaluation, either from medical, scientific, and ethical points of view. I appreciate the valuable input of the authors to spotlight an important issue of a clinical medicine. I hope that the practice of discussing thematic controversies will continue in the upcoming issues to ensure that the readers receive the up-todate views of opinion leaders.
We hope that the number of contributors to our journal will grow with time, since its visibility and readership are steadily increasing at the platforms of SCOPUS, eLibrary, Research-Gate, and other popular journal databases.